Citation Impact
Citing Papers
Identification of a Primary Target of Thalidomide Teratogenicity
2010 StandoutScience
Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging
2023 Standout
World Health Organization‐defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management
2014
Molecular imaging in drug development
2008 Standout
Animal models of human disease: zebrafish swim into view
2007 Standout
The Binary Classification of Protein Kinases
2021
Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple Myeloma
2003
Effect of Thalidomide in Hepatocellular Carcinoma: Assessment with Power Doppler US and Analysis of Circulating Angiogenic Factors
2005
Following TRAIL’s path in the immune system
2009
Targeting apoptosis in cancer therapy
2020 Standout
A systematic review of phase‐II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma
2006
Broadening horizons: the role of ferroptosis in cancer
2021 Standout
The use of novel agents in the treatment of relapsed and refractory multiple myeloma
2009
Thalidomide
2004
Drug Insight: thalidomide as a treatment for multiple myeloma
2005
Proteasome Inhibitors with Photocontrolled Activity
2014 StandoutNobel
Dissemination and publication of research findings: an updated review of related biases
2010 Standout
Improved survival in multiple myeloma and the impact of novel therapies
2007 Standout
Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate
2005
Hematological Problems in Pediatric Intensive Care
2013 Standout
Works of Marek Hus being referenced
Production of Proangiogenic Cytokines During Thalidomide Treatment of Multiple Myeloma
2002
Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma
2011
Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome
2011
Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number
2017
Thalidomide treatment of resistant or relapsed multiple myeloma patients.
2001
Stimulation of erythropoiesis by thalidomide in multiple myeloma patients: its influence on FasL, TRAIL and their receptors on erythroblasts.
2006